IDH1 and glioma: Vorasidenib had positive results in delaying progression of a specific form of glioma.179,180 It doubled progression-free survival in people with recurrent grade 2 glioma with isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) mutations.